192 related articles for article (PubMed ID: 36037447)
21. Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria.
Zhou P; Hong J
Acc Chem Res; 2021 Apr; 54(7):1623-1634. PubMed ID: 33720682
[TBL] [Abstract][Full Text] [Related]
22. Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections.
Montgomery JI; Brown MF; Reilly U; Price LM; Abramite JA; Arcari J; Barham R; Che Y; Chen JM; Chung SW; Collantes EM; Desbonnet C; Doroski M; Doty J; Engtrakul JJ; Harris TM; Huband M; Knafels JD; Leach KL; Liu S; Marfat A; McAllister L; McElroy E; Menard CA; Mitton-Fry M; Mullins L; Noe MC; O'Donnell J; Oliver R; Penzien J; Plummer M; Shanmugasundaram V; Thoma C; Tomaras AP; Uccello DP; Vaz A; Wishka DG
J Med Chem; 2012 Feb; 55(4):1662-70. PubMed ID: 22257165
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and structure-activity relationship evaluation of novel LpxC inhibitors as Gram-negative antibacterial agents.
Ding S; Dai RY; Wang WK; Cao Q; Lan LF; Zhou XL; Yang YS
Bioorg Med Chem Lett; 2018 Jan; 28(2):94-102. PubMed ID: 29233653
[TBL] [Abstract][Full Text] [Related]
24. Uridine-based inhibitors as new leads for antibiotics targeting Escherichia coli LpxC.
Barb AW; Leavy TM; Robins LI; Guan Z; Six DA; Zhou P; Hangauer MJ; Bertozzi CR; Raetz CR
Biochemistry; 2009 Apr; 48(14):3068-77. PubMed ID: 19256534
[TBL] [Abstract][Full Text] [Related]
25. A method to assay inhibitors of lipopolysaccharide synthesis.
Hernick M; Fierke CA
Methods Mol Med; 2008; 142():143-54. PubMed ID: 18437312
[TBL] [Abstract][Full Text] [Related]
26. N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.
Furuya T; Shapiro AB; Comita-Prevoir J; Kuenstner EJ; Zhang J; Ribe SD; Chen A; Hines D; Moussa SH; Carter NM; Sylvester MA; Romero JAC; Vega CV; Sacco MD; Chen Y; O'Donnell JP; Durand-Reville TF; Miller AA; Tommasi RA
Bioorg Med Chem; 2020 Dec; 28(24):115826. PubMed ID: 33160146
[TBL] [Abstract][Full Text] [Related]
27. Insights into the Zinc-Dependent Deacetylase LpxC: Biochemical Properties and Inhibitor Design.
Kalinin DV; Holl R
Curr Top Med Chem; 2016; 16(21):2379-430. PubMed ID: 27072691
[TBL] [Abstract][Full Text] [Related]
28. Screening for antibacterial inhibitors of the UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) using a high-throughput mass spectrometry assay.
Langsdorf EF; Malikzay A; Lamarr WA; Daubaras D; Kravec C; Zhang R; Hart R; Monsma F; Black T; Ozbal CC; Miesel L; Lunn CA
J Biomol Screen; 2010 Jan; 15(1):52-61. PubMed ID: 20019290
[TBL] [Abstract][Full Text] [Related]
29. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase of Escherichia coli is a zinc metalloenzyme.
Jackman JE; Raetz CR; Fierke CA
Biochemistry; 1999 Feb; 38(6):1902-11. PubMed ID: 10026271
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, biological evaluation and molecular docking studies of benzyloxyacetohydroxamic acids as LpxC inhibitors.
Szermerski M; Melesina J; Wichapong K; Löppenberg M; Jose J; Sippl W; Holl R
Bioorg Med Chem; 2014 Feb; 22(3):1016-28. PubMed ID: 24412340
[TBL] [Abstract][Full Text] [Related]
31. Treatment of human challenge and MDR strains of Neisseria gonorrhoeae with LpxC inhibitors.
John CM; Feng D; Jarvis GA
J Antimicrob Chemother; 2018 Aug; 73(8):2064-2071. PubMed ID: 29726994
[TBL] [Abstract][Full Text] [Related]
32. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens.
Tomaras AP; McPherson CJ; Kuhn M; Carifa A; Mullins L; George D; Desbonnet C; Eidem TM; Montgomery JI; Brown MF; Reilly U; Miller AA; O'Donnell JP
mBio; 2014 Sep; 5(5):e01551-14. PubMed ID: 25271285
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of Pseudomonas aeruginosa LpxC with its inhibitors in an acrB-deficient Escherichia coli strain.
Gao N; McLeod SM; Hajec L; Olivier NB; Lahiri SD; Bryan Prince D; Thresher J; Ross PL; Whiteaker JD; Doig P; Li AH; Hill PJ; Cornebise M; Reck F; Hale MR
Protein Expr Purif; 2014 Dec; 104():57-64. PubMed ID: 25240855
[TBL] [Abstract][Full Text] [Related]
34. The inhibitory and binding studies of methyl-sulfone hydroxamate based inhibitors against LpxC from drug resistant Moraxella catarrhalis using biophysical, biochemical and in silico approaches.
Sharma A; Kumar V; Pratap S; Kumar P
Int J Biol Macromol; 2018 Oct; 118(Pt B):1747-1762. PubMed ID: 30017978
[TBL] [Abstract][Full Text] [Related]
35. Bacterial Zinc Metalloenzyme Inhibitors: Recent Advances and Future Perspectives.
Di Leo R; Cuffaro D; Rossello A; Nuti E
Molecules; 2023 May; 28(11):. PubMed ID: 37298854
[TBL] [Abstract][Full Text] [Related]
36. Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis.
Barb AW; Zhou P
Curr Pharm Biotechnol; 2008 Feb; 9(1):9-15. PubMed ID: 18289052
[TBL] [Abstract][Full Text] [Related]
37. Molecular recognition by Escherichia coli UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase is modulated by bound metal ions.
Hernick M; Fierke CA
Biochemistry; 2006 Dec; 45(49):14573-81. PubMed ID: 17144651
[TBL] [Abstract][Full Text] [Related]
38. Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with Antibacterial Activity.
Yamada Y; Takashima H; Walmsley DL; Ushiyama F; Matsuda Y; Kanazawa H; Yamaguchi-Sasaki T; Tanaka-Yamamoto N; Yamagishi J; Kurimoto-Tsuruta R; Ogata Y; Ohtake N; Angove H; Baker L; Harris R; Macias A; Robertson A; Surgenor A; Watanabe H; Nakano K; Mima M; Iwamoto K; Okada A; Takata I; Hitaka K; Tanaka A; Fujita K; Sugiyama H; Hubbard RE
J Med Chem; 2020 Dec; 63(23):14805-14820. PubMed ID: 33210531
[TBL] [Abstract][Full Text] [Related]
39. Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC.
Kline T; Andersen NH; Harwood EA; Bowman J; Malanda A; Endsley S; Erwin AL; Doyle M; Fong S; Harris AL; Mendelsohn B; Mdluli K; Raetz CR; Stover CK; Witte PR; Yabannavar A; Zhu S
J Med Chem; 2002 Jul; 45(14):3112-29. PubMed ID: 12086497
[TBL] [Abstract][Full Text] [Related]
40. LpxC (UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase) inhibitors: A long path explored for potent drug design.
Kumar Pal S; Kumar S
Int J Biol Macromol; 2023 Apr; 234():122960. PubMed ID: 36565833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
